Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | YAP1 | P46937 | 2/20 | 0.43 |
| ▸ | TEAD4 | Q15561 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2719619 | 1.00 | ALDH1A1 (0.50) | ALDH1A1MEN1LMNAKMT2ACYP1A2 | |
| SCHEMBL2723040 | 0.84 | MAOB (0.54) | ALDH1A1MEN1LMNAKMT2AHDAC8 | |
| SCHEMBL2723038 | 0.84 | MAOB (0.54) | ALDH1A1MEN1LMNAKMT2AHDAC8 | |
| SCHEMBL6012016 | 0.83 | KMT2A (0.46) | ALDH1A1MEN1LMNAKMT2AHDAC8 | |
| SCHEMBL6011048 | 0.83 | ALDH1A1 (0.47) | ALDH1A1MEN1LMNAKMT2ACYP1A2 | |
| Hydrochloric Acid SCHEMBL2720118 | 0.82 | MEN1 (0.46) | ALDH1A1MEN1LMNAKMT2ACYP1A2 | |
| Hydrochloric Acid SCHEMBL2720115 | 0.82 | MEN1 (0.46) | ALDH1A1MEN1LMNAKMT2ACYP1A2 | |
| SCHEMBL14261851 | 0.80 | CYP1A2 (0.42) | ALDH1A1MEN1LMNAKMT2ACYP1A2 | |
| SCHEMBL14261783 | 0.79 | STS (0.54) | ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL6011019 | 0.78 | ALDH1A1 (0.43) | ALDH1A1YAP1TEAD4MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1785415-B1 | PIPERIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-20080070898-A1 | Piperidine Derivative or Pharmaceutically Acceptable Salt Thereof | ASTELLAS PHARMA INC. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1785415-A1 | PIPERIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Astellas Pharma Inc. (JP) | 2007-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070898-A1 | Piperidine Derivative or Pharmaceutically Acceptable Salt Thereof | TRPV1, TRPA1, CACNA1D | ALDH1A1 863/4885MEN1 2489/4885LMNA 4115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.